Physician profile
Patrick Desir
NPI 1700401650
$5,689.15
in general payments reported to CMS, 2019-2025
19 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.09 · 2022: $1,224 · 2023: $1,176 · 2024: $1,360 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,370.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.70 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $749.41 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $574.70 | 2022-2025 | Rexulti |
| Alkermes, INC. | $417.14 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $385.50 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $336.06 | 2022-2024 | Quviviq |
| Corium, LLC | $332.29 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.47 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $272.15 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $163.57 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $122.99 | 2024-2025 | Spravato, Invega |
| Ironshore Pharmaceuticals INC. | $90.41 | 2024 | |
| Lundbeck LLC | $56.01 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $55.78 | 2022 | |
| Collegium Pharmaceutical, INC. | $44.86 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $37.66 | 2022-2025 | Wellbutrin, Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.03 | 2025 | Rexulti |
| Vertical Pharmaceuticals, LLC | $19.53 | 2025 | Relexxii |
| Tms Neurohealth Centers INC. | $17.89 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Desir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.